Viet-Phap to oversee licensing, distribution, and sales of Hanmi 에볼루션 바카라 사이트's hypertension combination drug in Vietnam
[by Ji, Yong Jun] Hanmi Pharmaceutical announced on November 5 that it has entered into an exclusive supply and licensing agreement with Vietnamese pharmaceutical company Viet-Phap for the export of multiple hypertension combination drugs to the Vietnamese market.
The agreement was signed during CPHI Worldwide 2025, an international 에볼루션 바카라 사이트 and biotechnology exhibition held in Frankfurt, Germany, from October 28 to 30. The signing ceremony was attended by Park Jae-hyun, CEO of Hanmi 에볼루션 바카라 사이트, Nguyen Chi Dung, CEO of Viet-Phap.
Under the terms of the agreement, Hanmi 에볼루션 바카라 사이트 will supply finished combination drugs for hypertension, while Viet-Phap will oversee licensing, distribution, and sales in Vietnam. Building on this partnership, the two companies intend to work closely together to ensure the successful entry of Hanmi 에볼루션 바카라 사이트’s key new drugs into the Vietnamese market.
Viet-Phap is a privately owned 에볼루션 바카라 사이트 company headquartered in Hanoi, Vietnam. With more than 20 years of experience in 에볼루션 바카라 사이트 research and development (R&D), the company is recognized as one of the leading 에볼루션 바카라 사이트 firms in the Vietnamese market. Since its establishment in 2002, Viet-Phap has imported and distributed orphan drugs and original 에볼루션 바카라 사이트s across a wide range of treatment areas.
The Vietnamese hypertension market, valued at approximately USD 40 million annually and encompassing an estimated 15 million patients, continues to show steady growth. Leveraging its extensive experience and expertise in this rapidly growing market, Viet-Phap is expected to play a pivotal role in facilitating the successful introduction and stable establishment of Hanmi 에볼루션 바카라 사이트's flagship hypertension combination therapy portfolio in Vietnam. Through this collaboration, the two companies aim to expand access to hypertension treatments in Vietnam, address unmet medical needs among local patients, and improve the overall treatment landscape in the country.
"Through our partnership with Hanmi 에볼루션 바카라 사이트, we aim to introduce next-generation treatments to the Vietnamese market, thereby accelerating Viet-Phap's growth while contributing to the health and well-being of the Vietnamese population. Beyond hypertension treatments, we look forward to expanding our collaboration into additional therapeutic areas that address unmet medical needs," expressed Nguyen Chi Dung, CEO of Viet-Phap.
“Through this collaboration with Viet-Phap, we have established a strong foundation for our company’s flagship antihypertensive combination drug to gain a stable foothold in the Vietnamese market,” said Park Jae-hyun, CEO of Hanmi 에볼루션 바카라 사이트. “We will continue to provide active support and collaboration to ensure that local patients have easier access to effective antihypertensive treatments,” he added.